Christopher Comeau > Ropes & Gray LLP > Boston, United States > Lawyer Profile
Ropes & Gray LLP Offices
![Ropes & Gray LLP company logo](https://www.legal500.com/wp-content/uploads/sites/13/2022/05/50844.jpg?v=1653306080)
800 BOYLSTON STREET
BOSTON, MA 02199
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Christopher Comeau
![Christopher Comeau photo](/wp-content/themes/legal-500-main/default-lawyer-profile.jpg)
Work Department
Mergers & Acquisitions
Position
Partner
Career
https://www.ropesgray.com/en/biographies/c/christopher-d-comeau?AK=Christopher%20Comeau
Lawyer Rankings
United States > M&A/corporate and commercial > M&A: large deals ($1bn+)
Demonstrating significant expertise in the biotech and pharma sectors, the Ropes & Gray LLP practice is highly regarded for representing clients in strategic combination agreements and complex take-private sales. The firm represents a diverse array of domestic and global corporations, including Pfizer, Blackstone, and Medtronic, with Boston-based practice head Christopher Comeau noted for his ability to counsel these clients on strategic acquisitions and minority investments. Also in Boston, Mike Beauvais is an expert on private securities offerings and financings and Zachary Blume focuses on corporate governance issues, while New York-based lawyer Jackie Cohen has experience handling joint ventures and spin-offs. Further key contacts in New York include Ariel Deckelbaum, who concentrates primarily on restructuring transactions, and Carl Marcellino, who routinely acts for private equity funds on investments and leveraged buyouts.
Lawyer Rankings
Top Tier Firm Rankings
- Investment fund formation and management > Alternative/hedge funds
- Finance > Financial services regulation
- Dispute resolution > E-discovery
- Dispute resolution > M&A litigation: defense
- Dispute resolution > Securities litigation: defense
- Healthcare > Life sciences
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Dispute resolution > Securities litigation: defense
- Healthcare > Service providers
Firm Rankings
- Finance > Capital markets: high-yield debt offerings
- Finance > Capital markets: equity offerings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Tax > Not-for-profit (Fortune 1000 private foundations, national trade associations, and charities)
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Investment fund formation and management > Private equity funds (including venture capital)
- Tax > US taxes: non-contentious
- Antitrust > Cartel
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Intellectual property > Patents: litigation (International Trade Commission)
- Real estate > Real estate
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Securities litigation: defense
- Government > State attorneys general
- Labor and employment > Workplace and employment counseling
- Finance > Capital markets: high-yield debt offerings
- Finance > Fintech
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Finance > Structured finance: derivatives and structured products
- Media, technology and telecoms > Technology transactions
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Antitrust > Civil litigation/class actions: defense
- M&A/corporate and commercial > Venture capital and emerging companies
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- International trade > Customs, export controls and economic sanctions
- Finance > Structured finance: securitization
- M&A/corporate and commercial > Shareholder activism